Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 14/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 7/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168285 | 0.96 | ACE (0.45) | ACELTA4HACE2MMEMMEL1 | |
| SCHEMBL21168319 | 0.96 | ACE (0.45) | ACELTA4HACE2MMEMMEL1 | |
| SCHEMBL21168326 | 0.92 | ACE (0.46) | ACELTA4HACE2MMEMMEL1 | |
| SCHEMBL21168325 | 0.92 | ACE (0.46) | ACELTA4HACE2MMEMMEL1 | |
| SCHEMBL25476861 | 0.89 | ACE (0.40) | ACELTA4HMMEMMEL1F2 | |
| SCHEMBL19969548 | 0.89 | ACE (0.46) | ACELTA4HACE2MMEMMEL1 | |
| SCHEMBL19969264 | 0.89 | ACE (0.46) | ACELTA4HACE2MMEMMEL1 | |
| SCHEMBL21168347 | 0.87 | ACE (0.40) | ACEMMEMMEL1 | |
| SCHEMBL25476877 | 0.85 | ACE (0.41) | ACELTA4HACE2MMEMMEL1 | |
| SCHEMBL24595272 | 0.85 | MME (0.49) | ACELTA4HACE2MMEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-11311517-B2 | Combination of small molecule CD-47 inhibitors with other anti-cancer agents | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-04-26 | — | — | US | disclosed |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2021-05-13 | — | — | US | disclosed |
| US-20200147054-A1 | Combination of Small Molecule CD-47 Inhibitors with Other Anti-Cancer Agents | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311517-B2 | Combination of small molecule CD-47 inhibitors with other anti-cancer agents | CD47, CD63, CD99 | ACE 4765/4885LTA4H 4549/4885ACE2 4791/4885 |
| US-20200147054-A1 | Combination of Small Molecule CD-47 Inhibitors with Other Anti-Cancer Agents | CD47, CD63, CD99 | ACE 4765/4885LTA4H 4549/4885ACE2 4791/4885 |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | CD47, HIF1AN, PIK3R5 | ACE 4818/4885LTA4H 4359/4885ACE2 4566/4885 |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | ACE 4811/4885LTA4H 4332/4885ACE2 4528/4885 |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | ACE 4811/4885LTA4H 4332/4885ACE2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.